CTMX CytomX Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTMX

Price (delayed)

$1.79

Market cap

$118.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.51

Enterprise value

-$62.04M

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics, ...

Highlights
The gross profit is up by 42% year-on-year and by 34% since the previous quarter
CTMX's revenue is up by 42% year-on-year and by 34% since the previous quarter
CTMX's quick ratio has dropped by 62% year-on-year and by 25% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cytomx.com
Peers: OVID

Key stats

What are the main financial stats of CTMX
Market
Shares outstanding
66.23M
Market cap
$118.55M
Enterprise value
-$62.04M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.17
Earnings
Revenue
$53.16M
EBIT
-$99.32M
EBITDA
-$93.46M
Free cash flow
-$112.53M
Per share
EPS
-$1.51
Free cash flow per share
-$1.71
Book value per share
-$1.3
Revenue per share
$0.81
TBVPS
$3.94
Balance sheet
Total assets
$260.89M
Total liabilities
$346.64M
Debt
$13.98M
Equity
-$85.75M
Working capital
$84.49M
Liquidity
Debt to equity
-0.16
Current ratio
1.55
Quick ratio
1.51
Net debt/EBITDA
1.93
Margins
EBITDA margin
-175.8%
Gross margin
100%
Net margin
-186.8%
Operating margin
-190.6%
Efficiency
Return on assets
-38%
Return on equity
-666.3%
Return on invested capital
-649.4%
Return on capital employed
-91.7%
Return on sales
-186.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTMX stock price

How has the CytomX Therapeutics stock price performed over time
Intraday
5.29%
1 week
-2.72%
1 month
-16.74%
1 year
-33.46%
YTD
11.88%
QTD
11.88%

Financial performance

How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$53.16M
Gross profit
$53.16M
Operating income
-$101.34M
Net income
-$99.32M
Gross margin
100%
Net margin
-186.8%
CTMX's net margin is up by 43% since the previous quarter and by 40% year-on-year
The gross profit is up by 42% year-on-year and by 34% since the previous quarter
CTMX's revenue is up by 42% year-on-year and by 34% since the previous quarter
The company's operating margin rose by 42% QoQ and by 39% YoY

Growth

What is CytomX Therapeutics's growth rate over time

Valuation

What is CytomX Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.17
The EPS has grown by 25% from the previous quarter and by 17% YoY
The stock's P/S is 72% less than its 5-year quarterly average of 8.0 and 26% less than its last 4 quarters average of 3.0
CTMX's revenue is up by 42% year-on-year and by 34% since the previous quarter

Efficiency

How efficient is CytomX Therapeutics business performance
The ROIC has shrunk by 158% QoQ
CTMX's ROE has dropped by 86% since the previous quarter
The ROS has grown by 43% from the previous quarter and by 40% YoY
CTMX's return on assets is down by 27% year-on-year but it is up by 18% since the previous quarter

Dividends

What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTMX.

Financial health

How did CytomX Therapeutics financials performed over time
CTMX's total assets is 25% less than its total liabilities
The company's total liabilities has surged by 75% QoQ
CTMX's quick ratio has dropped by 62% year-on-year and by 25% since the previous quarter
CTMX's debt is 116% greater than its equity
The debt to equity has dropped by 130% since the previous quarter but it has soared by 100% year-on-year
CTMX's debt is down by 23% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.